Xeris Pharmaceuticals XERS

$ 3.08 0.65%

Quarterly report 2024-Q3
added 11-08-2024

Xeris Pharmaceuticals Balance Sheet 2011-2024 | XERS

Annual Balance Sheet Xeris Pharmaceuticals

	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Net Debt	127 M	66.7 M	20.8 M	49.4 M	38.8 M	-13.8 M	-42 M	-32.3 M	-	-	-	-	-
Long Term Debt	191 M	187 M	88.1 M	87 M	58.3 M	31.9 M	-	-	-	-	-	-	-
Long Term Debt Current	3.5 M	1.58 M	-	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	97.2 M	67.2 M	34.4 M	98 M	62.9 M	-	-	-	-	-
Total Current Liabilities	95.2 M	73.6 M	79 M	-	-	-	-	-	-	-	-	-	-
Total Liabilities	329 M	299 M	209 M	125 M	94.6 M	44.6 M	103 M	65.5 M	-	-	-	-	-
Deferred Revenue	-	-	-	-	-	232 K	234 K	263 K	-	-	-	-	-
Retained Earnings	-617 M	-555 M	-460 M	-337 M	-246 M	-121 M	-60.6 M	-34 M	-	-	-	-	-
Total Assets	323 M	345 M	304 M	159 M	109 M	120 M	45 M	33.5 M	-	-	-	-	-
Cash and Cash Equivalents	67.4 M	122 M	67.3 M	-	-	-	-	-	-	-	-	-	-
Book Value	-6.78 M	45.2 M	95.2 M	33.8 M	14.4 M	75.4 M	-57.8 M	-31.9 M	-	-	-	-	-
Total Shareholders Equity	-6.78 M	45.2 M	95.2 M	33.8 M	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Quarterly Balance Sheet Xeris Pharmaceuticals

	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Long Term Debt	216 M	230 M	230 M	191 M	190 M	188 M	188 M	187 M	139 M	138 M	138 M	88.1 M	87.7 M	-	-	87 M	87 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Liabilities	349 M	351 M	346 M	329 M	324 M	315 M	291 M	299 M	248 M	245 M	241 M	209 M	134 M	-	-	125 M	125 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-667 M	-651 M	-636 M	-617 M	-604 M	-591 M	-572 M	-555 M	-542 M	-520 M	-494 M	-460 M	-409 M	-	-	-337 M	-337 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Assets	321 M	332 M	337 M	323 M	328 M	329 M	321 M	345 M	303 M	319 M	338 M	304 M	131 M	-	-	159 M	159 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash and Cash Equivalents	59.2 M	57.6 M	62.7 M	67.4 M	46.1 M	46.2 M	51 M	122 M	84.1 M	95.3 M	104 M	67.3 M	59.5 M	63.6 M	66.6 M	37.6 M	37.6 M	-	-	19.5 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Book Value	-28.3 M	-19.3 M	-9.18 M	-6.78 M	3.86 M	13.6 M	30 M	45.2 M	55 M	73.9 M	96.5 M	95.2 M	-2.46 M	-	-	33.8 M	33.8 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Shareholders Equity	-28.3 M	-19.3 M	-9.18 M	-6.78 M	3.86 M	13.6 M	30 M	45.2 M	55 M	73.9 M	96.5 M	95.2 M	-2.46 M	19.9 M	44.4 M	33.8 M	33.8 M	24.4 M	27.1 M	14.4 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency